Dolly S. Chang, M.D., M.P.H., Ph.D. is the Chief Scientific Officer at Kodiak Sciences, joining the company in
2024 from Genentech. At Kodiak, Dr. Chang oversees pipeline development and advances transformative
therapies for retinal diseases. Dr. Chang is an accomplished ophthalmologist and biotech leader with extensive experience in clinical development across all stages of ophthalmic drug development. Prior to Kodiak, Dr. Chang was Group Medical Director at Genentech Research and Early Clinical Development (gRED), where she acted as the disease area expert in ophthalmology, co-led the Digital Health Team, and provided expertise in corporate development due diligence activities. At Genentech, she steered complex molecule programs across various development stages, championed new therapeutic areas including glaucoma neuroprotection, and was pivotal to ocular cell therapy collaboration and development.

Dr. Chang earned her M.D. from National Taiwan University, and her M.P.H. and Ph.D. from Johns Hopkins
University, where she completed her ophthalmology residency. She further specialized with a glaucoma
fellowship at Stanford University. Dr. Chang holds a position as Adjunct Clinical Assistant Professor at Stanford University’s Byers Eye Institute, continuing her clinical practice in cataract and glaucoma surgeries, research, and mentoring. Dr. Chang also serves on the external scientific advisory board for the Mary Tyler Moore Vision Initiative.